Analysis of determinants in filovirus glycoproteins required for tetherin antagonism

Viruses

Volumn 6, Issue 4, 2014, Pages 1654-1671

  Gnirß, Kerstin ^a,b   Fiedler, Marie ^a   Krämer Kühl, Annika ^a,b,e   Bolduan, Sebastian ^c   Mittler, Eva ^d,f   Becker, Stephan ^d   Schindler, Michael ^c   Pöhlmann, Stefan ^a,b  

^a GERMAN PRIMATE CENTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e Boehringer Ingelheim Veterinary Research Center GmbH and Co KG   (Germany)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ebola; Glycoprotein; Lassa; Tetherin

Indexed keywords

TETHERIN PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; BST2 PROTEIN, HUMAN; GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ARTICLE; CELL FUSION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EBOLA VIRUS; FILOVIRUS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LASSA VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN ANTAGONISM; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSMEMBRANE DOMAIN; VIRUS ENTRY; VIRUS PARTICLE; VIRUS RELEASE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL LINE; GENETICS; HOST PATHOGEN INTERACTION; MARBURG VIRUS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ANTIGENS, CD; CELL LINE; DNA MUTATIONAL ANALYSIS; EBOLAVIRUS; GLYCOPROTEINS; GPI-LINKED PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MARBURGVIRUS; VIRAL PROTEINS;

EID: 84898442087     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6041654     Document Type: Article

References (58)

1. Blanco-Melo, D.; Venkatesh, S.; Bieniasz, P.D. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 2012, 37, 399-411.
2. Harris, R.S.; Hultquist, J.F.; Evans, D.T. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 2012, 287, 40875-40883.
3. Hrecka, K.; Hao, C.; Gierszewska, M.; Swanson, S.K.; Kesik-Brodacka, M.; Srivastava, S.; Florens, L.; Washburn, M.P.; Skowronski, J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474, 658-661.
4. Laguette, N.; Sobhian, B.; Casartelli, N.; Ringeard, M.; Chable-Bessia, C.; Segeral, E.; Yatim, A.; Emiliani, S.; Schwartz, O.; Benkirane, M. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474, 654-657.
5. Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451, 425-430.
6. Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418, 646-650.
7. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427, 848-853.
8. Schoggins, J.W.; Wilson, S.J.; Panis, M.; Murphy, M.Y.; Jones, C.T.; Bieniasz, P.; Rice, C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472, 481-485.
9. Barrett, B.S.; Smith, D.S.; Li, S.X.; Guo, K.; Hasenkrug, K.J.; Santiago, M.L. A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS. Pathog. 2012, 8, e1002596.
10. Jones, P.H.; Mahauad-Fernandez, W.D.; Madison, M.N.; Okeoma, C.M. BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. Virology 2013, 444, 124-139.
11. Neil, S.J. The antiviral activities of tetherin. Curr. Top. Microbiol. Immunol. 2013, 371, 67-104.
12. Andrew, A.J.; Kao, S.; Strebel, K. C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J. Biol. Chem. 2011, 286, 39967-39981.
13. Perez-Caballero, D.; Zang, T.; Ebrahimi, A.; McNatt, M.W.; Gregory, D.A.; Johnson, M.C.; Bieniasz, P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139, 499-511.
14. Venkatesh, S.; Bieniasz, P.D. Mechanism of HIV-1 Virion Entrapment by Tetherin. PLoS Pathog. 2013, 9, e1003483.
15. Van Damme N.; Goff, D.; Katsura, C.; Jorgenson, R.L.; Mitchell, R.; Johnson, M.C.; Stephens, E.B.; Guatelli, J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3, 245-252.
16. Dube, M.; Roy, B.B.; Guiot-Guillain, P.; Binette, J.; Mercier, J.; Chiasson, A.; Cohen, E.A. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 2010, 6, e1000856.
17. Iwabu, Y.; Fujita, H.; Kinomoto, M.; Kaneko, K.; Ishizaka, Y.; Tanaka, Y.; Sata, T.; Tokunaga, K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284, 35060-35072.
18. Vigan, R.; Neil, S.J. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J. Virol. 2010, 84, 12958-12970.
19. Banning, C.; Votteler, J.; Hoffmann, D.; Koppensteiner, H.; Warmer, M.; Reimer, R.; Kirchhoff, F.; Schubert, U.; Hauber, J.; Schindler, M. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 2010, 5, e9344.
20. Schmidt, S.; Fritz, J.V.; Bitzegeio, J.; Fackler, O.T.; Keppler, O.T. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2011, 2, e00036-11.
21. Lau, D.; Kwan, W.; Guatelli, J. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J. Virol. 2011, 85, 9834-9846.
22. Andrew, A.J.; Miyagi, E.; Strebel, K. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 2011, 85, 2611-2619.
23. Douglas, J.L.; Viswanathan, K.; McCarroll, M.N.; Gustin, J.K.; Fruh, K.; Moses, A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 2009, 83, 7931-7947.
24. Mitchell, R.S.; Katsura, C.; Skasko, M.A.; Fitzpatrick, K.; Lau, D.; Ruiz, A.; Stephens, E.B.; Margottin-Goguet, F.; Benarous, R.; Guatelli, J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009, 5, e1000450.
25. Kaletsky, R.L.; Francica, J.R.; Agrawal-Gamse, C.; Bates, P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. USA 2009, 106, 2886-2891.
26. Kühl, A.; Banning, C.; Marzi, A.; Votteler, J.; Steffen, I.; Bertram, S.; Glowacka, I.; Konrad, A.; Sturzl, M.; Guo, J.T.; et al. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 2011, 204, S850-S860.
27. Radoshitzky, S.R.; Dong, L.; Chi, X.; Clester, J.C.; Retterer, C.; Spurgers, K.; Kuhn, J.H.; Sandwick, S.; Ruthel, G.; Kota, K.; et al. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 2010, 84, 10569-10580.
28. Lopez, L.A.; Yang, S.J.; Hauser, H.; Exline, C.M.; Haworth, K.G.; Oldenburg, J.; Cannon, P.M. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 2010, 84, 7243-7255.
29. Rollason, R.; Dunstan, K.; Billcliff, P.G.; Bishop, P.; Gleeson, P.; Wise, H.; Digard, P.; Banting, G. Expression of HIV-1 Vpu Leads to Loss of the Viral Restriction Factor CD317/Tetherin from Lipid Rafts and Its Enhanced Lysosomal Degradation. PLoS One 2013, 8, e75680.
30. Sakuma, T.; Noda, T.; Urata, S.; Kawaoka, Y.; Yasuda, J. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 2009, 83, 2382-2385.
31. Mittler, E.; Kolesnikova, L.; Strecker, T.; Garten, W.; Becker, S. Role of the transmembrane domain of marburg virus surface protein GP in assembly of the viral envelope. J. Virol. 2007, 81, 3942-3948.
32. Feldmann, H.; Nichol, S.T.; Klenk, H.D.; Peters, C.J.; Sanchez, A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 1994, 199, 469-473.
33. Lenz, O.; ter, M.J.; Klenk, H.D.; Seidah, N.G.; Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. USA 2001, 98, 12701-12705.
34. Volchkov, V.E.; Feldmann, H.; Volchkova, V.A.; Klenk, H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 1998, 95, 5762-5767.
35. Volchkov, V.E.; Volchkova, V.A.; Stroher, U.; Becker, S.; Dolnik, O.; Cieplik, M.; Garten, W.; Klenk, H.D.; Feldmann, H. Proteolytic processing of Marburg virus glycoprotein. Virology 2000, 268, 1-6.
36. Wool-Lewis, R.J.; Bates, P. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J. Virol. 1999, 73, 1419-1426.
37. Manicassamy, B.; Wang, J.; Rumschlag, E.; Tymen, S.; Volchkova, V.; Volchkov, V.; Rong, L. Characterization of Marburg virus glycoprotein in viral entry. Virology 2007, 358, 79-88.
38. Mittler, E.; Kolesnikova, L.; Hartlieb, B.; Davey, R.; Becker, S. The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection. J. Virol. 2011, 85, 8188-8196.
39. Ito, H.; Watanabe, S.; Sanchez, A.; Whitt, M.A.; Kawaoka, Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 1999, 73, 8907-8912.
40. Brauburger, K.; Hume, A.J.; Muhlberger, E.; Olejnik, J. Forty-five years of Marburg virus research. Viruses 2012, 4, 1878-1927.
41. Nakayama, E.; Saijo, M. Animal models for Ebola and Marburg virus infections. Front. Microbiol. 2013, 4, 267.
42. Hofmann-Winkler, H.; Kaup, F.; Pöhlmann, S. Host cell factors in filovirus entry: novel players, new insights. Viruses 2012, 4, 3336-3362.
43. Miller, E.H.; Chandran, K. Filovirus entry into cells-New insights. Curr. Opin. Virol. 2012, 2, 206-214.
44. Lopez, L.A.; Yang, S.J.; Exline, C.M.; Rengarajan, S.; Haworth, K.G.; Cannon, P.M. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J. Virol. 2012, 86, 5467-5480.
45. Gao, F.; Li, Y.; Decker, J.M.; Peyerl, F.W.; Bibollet-Ruche, F.; Rodenburg, C.M.; Chen, Y.; Shaw, D.R.; Allen, S.; Musonda, R.; et al. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retroviruses 2003, 19, 817-823.
46. Nguyen, K.L.; llano, M.; Akari, H.; Miyagi, E.; Poeschla, E.M.; Strebel, K.; Bour, S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004, 319, 163-175.
47. Simmons, G.; Reeves, J.D.; Grogan, C.C.; Vandenberghe, L.H.; Baribaud, F.; Whitbeck, J.C.; Burke, E.; Buchmeier, M.J.; Soilleux, E.J.; Riley, J.L.; et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003, 305, 115-123.
48. Marzi, A.; Akhavan, A.; Simmons, G.; Gramberg, T.; Hofmann, H.; Bates, P.; Lingappa, V.R.; Pöhlmann, S. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J. Virol. 2006, 80, 6305-6317.
49. Kühl, A.; Hoffmann, M.; Muller, M.A.; Munster, V.J.; Gnirss, K.; Kiene, M.; Tsegaye, T.S.; Behrens, G.; Herrler, G.; Feldmann, H.; et al. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J. Infect. Dis. 2011, 204, S840-S849.
50. Marzi, A.; Gramberg, T.; Simmons, G.; Möller, P.; Rennekamp, A.J.; Krumbiegel, M.; Geier, M.; Eisemann, J.; Turza, N.; Saunier, B.; et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 2004, 78, 12090-12095.
51. Sauter, D.; Schindler, M.; Specht, A.; Landford, W.N.; Munch, J.; Kim, K.A.; Votteler, J.; Schubert, U.; Bibollet-Ruche, F.; Keele, B.F.; et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6, 409-421.
52. Connor, R.I.; Chen, B.K.; Choe, S.; Landau, N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206, 935-944.
53. Niwa, H.; Yamamura, K.; Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108, 193-199.
54. Lucht, A.; Grunow, R.; Otterbein, C.; Moller, P.; Feldmann, H.; Becker, S. Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus. Med. Microbiol. Immunol. 2004, 193, 181-187.
55. Mattheyses, A.L.; Simon, S.M.; Rappoport, J.Z. Imaging with total internal reflection fluorescence microscopy for the cell biologist. J. Cell Sci. 2010, 123, 3621-3628.
56. Volocity 3D Image Analysis Software, version 6.3; Perkin Elmer: Waltham, MA, USA, 2014.
57. Carette, J.E.; Raaben, M.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; Mulherkar, N.; Kuehne, A.I.; Kranzusch, P.J.; Griffin, A.M.; Ruthel, G.; et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011, 477, 340-343.
58. Cote, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Filone, C.M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477, 344-348.